Quick Answer
Keros Therapeutics, Inc. reported Stockholders Equity of $303.13 million for fiscal year 2025.
Keros Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $303.13M | -47.0% |
| 2024 | $571.55M | +72.0% |
| 2023 | $332.21M | +19.7% |
| 2022 | $277.42M | +14.1% |
| 2021 | $243.17M | -7.1% |
| 2020 | $261.72M | +1445.9% |
| 2019 | -$19.45M | -170.7% |
| 2018 | -$7.18M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $703.58M | +32.0% | -0.4% |
| June 30, 2025 | $706.73M | +67.9% | -3.0% |
| March 31, 2025 | $728.87M | +60.6% | +27.5% |
| December 31, 2024 | $571.55M | +72.0% | +7.3% |
| September 30, 2024 | $532.84M | +80.1% | +26.6% |
| June 30, 2024 | $420.92M | +29.0% | -7.3% |
| March 31, 2024 | $453.95M | +27.9% | +36.6% |
| December 31, 2023 | $332.21M | +19.7% | +12.3% |
- Keros Therapeutics, Inc. showed a decrease of -47.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Keros Therapeutics, Inc.’s stockholders equity has grown by 4320.1% (from -$7.18 million to $303.13 million).
- The most recent figure is from Keros Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: